Research Study

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Principal Investigator 
Theodore Steiner

Overview

Body Locations and Systems 
Clostridium Difficile Infections
ClinicalTrials.gov# 
NCT02589847
Status 
Recruiting
Study Start/End 
Mar 10, 2016 to Mar 10, 2018
Locations 
Diamond Health Care Centre
Name/Title 
Kessie Xu, Study Coordinator
Phone 
604-875-4111 ext.69487
Purpose of Study 

This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI). Enrolled subjects will receive one treatment with RBX2660 (microbiota suspension).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.